Cirrhosis

Cirrhosis – High‑Yield Study Guide for Medical Students

Definition

Cirrhosis is the end stage of chronic liver injury characterized by diffuse fibrosis, regenerative nodule formation, and distortion of normal hepatic architecture, leading to impaired liver function and increased intrahepatic vascular resistance. It represents an irreversible stage of chronic liver disease, although complications and progression can often be modified.

Epidemiology

Cirrhosis is a major global cause of morbidity and mortality and underlies most cases of portal hypertension, variceal bleeding, and hepatocellular carcinoma (HCC). The most common etiologies vary geographically, but include:

• Chronic viral hepatitis: Hepatitis B and C historically dominant worldwide; vaccination for HBV and antivirals have shifted patterns in many regions.[1](https://europepmc.org/article/MED/41767365)[4](https://europepmc.org/article/MED/41788631)
• Alcohol-associated liver disease: Major cause in many high‑income countries.
• Metabolic dysfunction–associated steatotic liver disease (MASLD) and MASH: Increasingly prevalent, including in lean individuals; associated with cardiovascular complications and contributes to cirrhosis and arrhythmia risk.[3](https://europepmc.org/article/MED/41724180)
• Autoimmune and cholestatic diseases: Autoimmune hepatitis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC).
• Genetic/metabolic: Hemochromatosis, Wilson disease, alpha‑1 antitrypsin deficiency.

Men are more frequently affected than women for alcohol-related and viral causes. MASLD/MASH prevalence parallels obesity, diabetes, and metabolic syndrome epidemics.

Pathophysiology

Cirrhosis develops from chronic hepatocellular injury and inflammation that activate hepatic stellate cells and portal fibroblasts. These cells transform into myofibroblasts that deposit type I and III collagen and other extracellular matrix components in the space of Disse and portal tracts. Progressive fibrosis bridges portal tracts and central veins, creating fibrous septa and regenerative nodules, which distort vascular architecture.

The architectural distortion increases intrahepatic vascular resistance, leading to portal hypertension (portal vein pressure >5 mmHg; clinically significant ≥10–12 mmHg). Splanchnic vasodilation, driven by nitric oxide and other mediators, causes an effective arterial blood volume decrease, activating RAAS, sympathetic nervous system, and ADH, promoting sodium and water retention with ascites and edema. Chronic systemic inflammation, altered metabolism (including lactate and glycolysis-related changes), and neurohormonal dysregulation further worsen hemodynamics and organ dysfunction.[2](https://europepmc.org/article/MED/41783047)[3](https://europepmc.org/article/MED/41724180)

Loss of functional hepatocyte mass plus portosystemic shunting leads to impaired synthetic function (low albumin, coagulopathy), detoxification failure (hyperammonemia, hepatic encephalopathy), impaired immune surveillance (infections, sepsis), and increased risk of hepatocarcinogenesis (HCC).

Clinical Presentation

Cirrhosis may be compensated (asymptomatic or nonspecific symptoms) or decompensated (overt complications). Many patients are diagnosed incidentally on labs or imaging.

Symptoms

• Fatigue, malaise, anorexia, weight loss
• Abdominal distention from ascites, early satiety
• Pruritus (especially in cholestatic disease)
• Jaundice, dark urine, pale stools (later disease or cholestasis)
• Cognitive changes: sleep–wake reversal, confusion, asterixis (hepatic encephalopathy)
• Features of complications: hematemesis/melena (variceal bleed), dyspnea or pleuritic pain (hepatic hydrothorax), lower extremity edema

Physical Examination

• General: Muscle wasting, cachexia, temporal wasting
• Skin: Jaundice, spider angiomas, palmar erythema, telangiectasias, bruising, excoriations
• Endocrine/gonadal: Gynecomastia, testicular atrophy, decreased body hair, menstrual irregularities
• Abdomen: Hepatomegaly (early) or small nodular liver (late), splenomegaly, shifting dullness and fluid wave (ascites), caput medusae, umbilical hernia
• Neurologic: Asterixis, hyperreflexia, cognitive slowing in encephalopathy

Major Complications

• Portal hypertension with varices (esophageal, gastric, ectopic) and portal hypertensive gastropathy
• Ascites and spontaneous bacterial peritonitis (SBP)
• Hepatic encephalopathy
• Hepatorenal syndrome (HRS)
• Hepatopulmonary syndrome and portopulmonary hypertension
• Coagulopathy and clinically relevant bleeding (though rebalanced hemostasis)
• Hepatocellular carcinoma (HCC)

Diagnosis

Diagnosis relies on clinical context, laboratory tests, noninvasive fibrosis assessment, imaging, and occasionally liver biopsy.

Laboratory Studies

• Liver enzymes: AST/ALT may be normal or mildly elevated; AST > ALT in alcohol-associated disease.
• Synthetic function: Low albumin, elevated INR/PT, low fibrinogen.
• Bilirubin: Elevated total and direct bilirubin with cholestasis or advanced disease.
• Cholestatic markers: Elevated alkaline phosphatase and GGT in cholestatic etiologies (PBC, PSC, biliary obstruction).
• Hematologic: Thrombocytopenia (splenic sequestration), anemia (chronic disease, GI blood loss), leukopenia.
• Etiologic workup: Viral hepatitis serologies (HBV, HCV), autoimmune markers, iron studies, ceruloplasmin, alpha‑1 antitrypsin level/phenotype, metabolic risk profile (lipids, HbA1c).

Noninvasive Fibrosis Assessment

• Serum scores: FIB‑4, APRI, NAFLD fibrosis score to estimate advanced fibrosis.
• Elastography: Transient elastography (FibroScan), shear-wave elastography, MR elastography to measure liver stiffness; higher stiffness correlates with advanced fibrosis and portal hypertension.

Imaging

• Ultrasound: Nodular liver surface, coarse echotexture, splenomegaly, portal vein dilation, collaterals, ascites. Doppler assesses portal and hepatic venous flow.
• CT/MRI: Demonstrate morphologic changes, regenerative nodules, collaterals, and screen for HCC. In surgical contexts (e.g., hepatectomy planning), advanced imaging and intraoperative fluorescence guidance can delineate segments and vascular anatomy.[5](https://europepmc.org/article/MED/41688835)

Liver Biopsy

Liver biopsy is not always required but is considered when the diagnosis or etiology is uncertain, when noninvasive tests are discordant, or in cases where staging will change management. Histology shows bridging fibrosis and regenerative nodules with etiology‑specific features (e.g., interface hepatitis in autoimmune hepatitis, steatohepatitis in MASH).

Staging and Prognostic Scores

• Child–Pugh score: Uses bilirubin, albumin, INR, ascites, and encephalopathy to classify into A, B, or C for prognosis and drug dosing.
• MELD (Model for End‑Stage Liver Disease): Based on bilirubin, creatinine, INR (and sometimes sodium) to predict short‑term mortality and determine liver transplant priority.
• Compensated vs decompensated: Decompensation defined by ascites, variceal bleeding, encephalopathy, or jaundice; marks a major drop in survival and transplant‑related considerations.

Management Overview

Management of cirrhosis focuses on: (1) eliminating or controlling the underlying cause, (2) preventing and treating complications of portal hypertension and liver failure, (3) monitoring for HCC, and (4) assessing for liver transplantation.

Etiology‑Directed Therapy

• Alcohol-associated liver disease: Complete alcohol abstinence; behavioral therapy; pharmacologic support (e.g., acamprosate, naltrexone) as appropriate.
• Viral hepatitis: Antiviral therapy for HBV and direct‑acting antivirals for HCV can halt or partially reverse fibrosis and reduce decompensation and HCC risk.[1](https://europepmc.org/article/MED/41767365)
• MASLD/MASH: Weight loss (7–10% body weight), control of diabetes, dyslipidemia, and cardiovascular risk; consideration of emerging pharmacologic therapies, especially in lean MASH patients given their cardiovascular and arrhythmia risk.[3](https://europepmc.org/article/MED/41724180)
• Autoimmune hepatitis: Glucocorticoids ± azathioprine.
• PBC: Ursodeoxycholic acid; obeticholic acid or other agents in selected cases.
• PSC: No proven antifibrotic therapy; manage strictures, surveil for cholangiocarcinoma and colon cancer (in IBD).
• Genetic/metabolic diseases: Phlebotomy for hemochromatosis, chelation for Wilson disease, augmentation or transplant for alpha‑1 antitrypsin deficiency.

Management of Portal Hypertension and Varices

• Screening endoscopy at diagnosis of cirrhosis (or guided by elastography and platelet counts) to detect esophageal/gastric varices.
• Primary prophylaxis of large/high‑risk varices with nonselective beta blockers (e.g., propranolol, nadolol, carvedilol) or endoscopic variceal ligation.
• Acute variceal bleeding: Resuscitation, vasoactive drugs (terlipressin, octreotide, or somatostatin), prophylactic antibiotics, urgent endoscopic ligation ± sclerotherapy; consider TIPS in refractory bleeding.
• Secondary prophylaxis after a variceal bleed with combination of nonselective beta blocker plus periodic endoscopic ligation.

Ascites and Spontaneous Bacterial Peritonitis (SBP)

• Diet: Sodium restriction (~2 g/day); fluid restriction if severe hyponatremia.
• Diuretics: Spironolactone (typically starting 100 mg) ± furosemide (40 mg) in a 100:40 ratio; titrate carefully to avoid renal dysfunction and electrolyte disturbances.
• Large volume paracentesis for tense ascites with intravenous albumin replacement (usually 6–8 g/L removed) to prevent circulatory dysfunction.
• SBP diagnosis: Paracentesis with ascitic fluid PMN ≥250/mm³; culture often positive but not required for diagnosis.
• SBP treatment: Empiric third‑generation cephalosporin (e.g., cefotaxime) or alternatives based on local resistance; albumin in high‑risk patients.
• SBP prophylaxis: Long‑term oral antibiotics (e.g., norfloxacin, ciprofloxacin, or TMP‑SMX) in high‑risk settings (prior SBP, low protein ascites with renal or liver failure).
• Refractory ascites: Consider repeated large-volume paracenteses, TIPS, and transplant evaluation.

Hepatic Encephalopathy (HE)

• Identify and treat precipitants: Infection, GI bleed, electrolyte disturbances, constipation, sedatives, dehydration, renal failure.
• First-line therapy: Nonabsorbed disaccharide (lactulose) titrated to 2–3 soft stools/day.
• Adjunctive therapy: Rifaximin added for recurrent episodes or lactulose failure.
• Supportive care: Nutrition, avoidance of sedatives and unnecessary protein restriction (moderate protein intake is usually acceptable).

Hepatorenal Syndrome (HRS) and Other Organ Complications

• HRS: Functional renal failure due to severe vasodilation and renal vasoconstriction; treat with vasoconstrictors (e.g., terlipressin, midodrine + octreotide) and albumin; definitive therapy is liver transplantation.
• Hepatopulmonary syndrome: Hypoxemia from intrapulmonary vasodilation; supplemental oxygen and transplant evaluation.
• Portopulmonary hypertension: Pulmonary arterial hypertension in portal hypertension; may require PAH‑specific therapy and influences transplant eligibility.

Hepatocellular Carcinoma (HCC) Surveillance

• Surveillance for HCC in all cirrhotic patients (and some noncirrhotic high‑risk groups) with ultrasound every 6 months, with or without alpha‑fetoprotein (AFP).
• Suspicious lesions (≥1 cm) should undergo multiphasic CT or MRI with characteristic arterial enhancement and venous washout; nonclassic lesions may require biopsy.
• Treatment options range from ablation, resection, and transplantation to locoregional therapies and systemic therapy depending on tumor burden and liver function.

Liver Transplantation

• Indications: Decompensated cirrhosis with recurrent complications (e.g., refractory ascites, recurrent variceal bleeding, recurrent HE, HRS), MELD‑based high short‑term mortality, and selected HCC within transplant criteria.
• Evaluation includes assessment of cardiopulmonary status, psychosocial factors, abstinence in alcohol‑related disease, and control of comorbid conditions (e.g., metabolic disease in MASLD/MASH).[3](https://europepmc.org/article/MED/41724180)
• Posttransplant survival is generally excellent when patients are selected appropriately; underlying etiologies such as HBV, HCV, and metabolic disease require ongoing management to prevent recurrence.

Prevention and Public Health Considerations

• HBV vaccination for general population and especially healthcare workers and students; improving coverage and knowledge reduces chronic infection and cirrhosis burden.[1](https://europepmc.org/article/MED/41767365)[4](https://europepmc.org/article/MED/41788631)
• Harm reduction and screening in high‑risk groups for HBV/HCV.
• Alcohol control policies, brief interventions, and treatment programs.
• Obesity and metabolic syndrome prevention and treatment to reduce MASLD/MASH incidence.

Key Clinical Pearls

• Compensated vs decompensated: The single most important prognostic distinction; onset of ascites, variceal bleeding, encephalopathy, or jaundice marks decompensation.
• Always search for etiology: Multiple parallel causes (e.g., alcohol + MASH + viral hepatitis) are common and additive.
• Early etiologic therapy (e.g., antivirals for HBV/HCV, abstinence from alcohol, metabolic control) can halt or partially reverse fibrosis and reduce complications and HCC risk.
• Every admission of a cirrhotic with ascites warrants diagnostic paracentesis to rule out SBP.
• Variceal bleeding is portal hypertension until proven otherwise; think resuscitation, vasoactive drugs, antibiotics, and urgent endoscopy.
• Low sodium, rising creatinine, and worsening ascites often herald circulatory dysfunction and possible HRS; review diuretics, nephrotoxins, and volume status early.
• HCC surveillance every 6 months in cirrhosis is standard of care; missed surveillance is a common cause of late HCC detection.
• Cirrhosis is a multisystem disease: Cardiovascular, renal, and pulmonary complications (including arrhythmias in lean MASH) significantly impact prognosis.[3](https://europepmc.org/article/MED/41724180)
• Transplant referral should be considered as soon as decompensation occurs or if MELD score is high, rather than waiting for terminal decline.